Your session is about to expire
← Back to Search
Anti-metabolites
Melphalan for Acute Myeloid Leukemia
Phase 2
Waitlist Available
Led By Scott Solomon, MD
Research Sponsored by Northside Hospital, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 2 years
Awards & highlights
Study Summary
This trial is testing if a new immunotherapy can help patients with a type of leukemia that are not candidates for stem cell transplant.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 2 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~2 years
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Number of Patients With 2-year Relapse Risk
Secondary outcome measures
Assess Safety of Pembrolizumab by Recording the Number of Participants With Treatment-related Adverse Events
Trial Design
1Treatment groups
Experimental Treatment
Group I: Lymphodepletion plus PembrolizumabExperimental Treatment3 Interventions
Fludarabine & Melphalan followed by autologous stem cell transplantation. Pembrolizumab will begin on Day +1.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludarabine
2012
Completed Phase 3
~1080
Melphalan
2008
Completed Phase 3
~1500
Pembrolizumab
2017
Completed Phase 2
~2010
Find a Location
Who is running the clinical trial?
Northside Hospital, Inc.Lead Sponsor
24 Previous Clinical Trials
1,071 Total Patients Enrolled
Merck Sharp & Dohme LLCIndustry Sponsor
3,906 Previous Clinical Trials
5,064,798 Total Patients Enrolled
Scott Solomon, MDPrincipal InvestigatorBlood and Marrow Transplant Group of Georgia
6 Previous Clinical Trials
20,232 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger